PTB Inhibition and miR-9 Agents for Neuronal Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current regenerative medicine strategies for neurodegenerative disorders face limitations in effectively trans-differentiating non-neuronal cells into functional neurons, particularly in elderly subjects due to age-related restrictions and reduced expression of miR-9 and miR-124, which impede neuronal reprogramming efficiency.
Innovation Solution
The use of a PTB inhibition agent and a miR-9 agent, potentially combined with miR-124, encoded in viral vectors such as AAV, to suppress PTB expression and enhance miR-9 activity in non-neuronal cells, facilitating their conversion into functional neurons within the brain, thereby overcoming age-related barriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional regenerative medicine strategies using pluripotent cells are employed, then cell replacement can be achieved, but efficacy is limited in neurodegenerative disorders and elderly subjects
Solution Approach 1:
The patent introduces PTB (polypyrimidine tract-binding protein) as a key intermediary that blocks neuronal reprogramming in non-neuronal cells. By inhibiting PTB using antisense oligonucleotides or small molecules, the patent removes this molecular barrier, enabling efficient trans-differentiation of non-neuronal cells into functional neurons. This intermediary mechanism explains why conventional approaches fail and provides a specific target for overcoming age-related restrictions.
Solution Approach 2:
The patent employs dual-miRNA approach (miR-9 and miR-124) to change the molecular parameters within non-neuronal cells. These miRNAs work together to reprogram gene expression profiles, transforming the cellular state from non-neuronal to neuronal. This parameter change strategy overcomes the age-related decline in reprogramming efficiency by artificially restoring the molecular conditions necessary for neuronal conversion.
2Adaptability or versatility
If trans-differentiation strategies are used to leverage cellular plasticity, then existing endogenous cells can be converted, but age-related restrictions reduce reprogramming efficiency in elderly subjects
Solution Approach 1:
The patent applies preliminary anti-action by pre-inhibiting PTB expression before attempting neuronal reprogramming. By using antisense oligonucleotides or small molecule inhibitors to suppress PTB beforehand, the patent prevents the molecular block that would otherwise prevent successful trans-differentiation. This preliminary intervention is crucial for overcoming age-related restrictions, as PTB expression increases with age and naturally blocks reprogramming in elderly subjects.
Solution Approach 2:
The patent performs preliminary action by first establishing the necessary molecular conditions (PTB inhibition and miRNA overexpression) before the actual neuronal conversion can occur. This preparatory step ensures that the cellular environment is primed for successful reprogramming, addressing the age-related decline in endogenous reprogramming capacity by artificially creating the required molecular conditions.
3Productivity
If PTB inhibition alone is applied, then some neuronal conversion occurs, but efficiency remains insufficient for effective treatment of neurodegenerative disorders
Solution Approach 1:
The patent uses a composite molecular approach by combining multiple miRNAs (miR-9 and miR-124) that work synergistically to enhance neuronal reprogramming. This composite strategy is more effective than single-miRNA or single-inhibitor approaches, as the miRNAs target different aspects of neuronal gene expression and collectively overcome the limitations of PTB inhibition alone, ensuring both efficiency and functional reliability of generated neurons.
Data Source
AI summary
Provided herein are compositions and methods for reprogramming a non-neuronal cell to a neuron. Aspects of the present disclosure relate to compositions and methods for transdifferentiating an age-restricted non-neuronal cell into a neuron. Also provided herein is a method of treating neurodegenerative disease by reprogramming region or anatomy specific non-neuronal cells into specific types of functionalized neurons.